Systemic sclerosis
Conditions
Interventions
single arm:JAK inhibitors
Sponsors
Dermatology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as SSC according to the latest ACR / EULAR classification diagnostic criteria; 2. Aged >= 18 years; 3. Patients with onset of systemic sclerosis (defined as the first non Renault symptom) = 50%; (Note: before participating in the drug treatment, those who take no more than 10 mg prednisone or stable dose of mycophenolate mofetil or methotrexate for at least 6 months SSc and meet the above conditions in 1.2.3.4 shall be included in the study group; the patients in the study group are allowed to combine with other drugs at the same time, such as drugs for improving blood circulation.)
Exclusion criteria
Exclusion criteria: 1. Patients with other connective tissue diseases; 2. Patients with infection; 3. Pregnancy or preparation; 4. Patients with chronic liver disease or liver transaminase level exceeding the upper limit of normal range by 1.5 times or more; 5) Patients with forced expiratory volume / forced vital capacity = 160 mmHg and / or diastolic blood pressure > 100 mmHg) during treatment; 10. With severe cardiovascular disease (history of myocardial infarction or unstable angina within 6 months before screening, and history of thrombotic events (including stroke and transient ischemic attack) within 12 months before screening); 11. Patients treated with mycophenolate mofetil or methotrexate in an unstable background; 12. With a history of or potential for malignancy; 13. Patients with psychosis or non cooperative treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin sclerosis;pulmonary fibrosis; | — |
Countries
China
Contacts
Public ContactYunsheng Liang
Dermatology Hospital of Southern Medical University
Outcome results
None listed